Quick answer
What is known about CJC-1295 pharmacokinetics? For the albumin-binding DAC form, a rat study reported plasma presence beyond 72 hours, with an albumin-associated species from 15 minutes to beyond 24 hours. For the no-DAC form there are fewer primary data; it lacks the albumin anchor and is described as short-lived, minutes to tens of minutes in animal models. The mechanism of the difference is established: native GHRH is cleaved at its N-terminus in plasma within minutes (17 minutes by HPLC in vitro for the native 44-mer). V8 lists the no-DAC peptide for laboratory research use only.
Pharmacokinetic statements about peptides travel badly. A half-life measured for one molecule in one species by one method is repeated as a property of a family of compounds, and the form (DAC or no DAC), the matrix (plasma in vitro versus animal in vivo) and the assay (immunoreactivity versus HPLC) disappear. This article puts those qualifiers back. It states what the primary papers measured, explains the two mechanisms that set persistence, and gives the formulas needed to reason about it. For laboratory research use only; not for human consumption.
Two mechanisms set how long a GHRH analog lasts
Enzymatic cleavage. Frohman and colleagues (1986) incubated native GRH(1-44)-NH2 with human plasma and measured it by radioimmunoassay, HPLC and bioassay. Immunoreactivity decayed with a half-life of 63 minutes, but HPLC showed the intact peptide disappearing faster, with a half-life of 17 minutes, as a less hydrophobic product appeared that was GRH(3-44)-NH2 with less than 10−3 of the biological activity. The difference between 63 and 17 minutes is the point: an immunoassay that recognizes the inactive product overstates how long the active molecule lasts. The enzyme is a dipeptidyl peptidase, and the family’s role in inactivating regulatory peptides is reviewed by Mentlein (1999).
Binding to a carrier. Jetté and colleagues (2005) added a maleimido group to hGRF(1-29) so that it bonds to the free thiol of Cys34 on albumin. The conjugates showed enhanced stability to dipeptidyl peptidase IV in vitro. The lead compound, CJC-1295, was present in plasma beyond 72 hours in rats, and a Western blot showed an immunoreactive species on the albumin band from 15 minutes to beyond 24 hours.
What has been measured, and where
| Molecule | System | Reported persistence | Method | Source |
|---|---|---|---|---|
| Native GRH(1-44)-NH2 | Human plasma, in vitro | t½ 17 min (intact peptide) | HPLC | Frohman and colleagues, 1986 |
| Native GRH(1-44)-NH2 | Human plasma, in vitro | t½ 63 min (total immunoreactivity) | Radioimmunoassay | Frohman and colleagues, 1986 |
| CJC-1295 (DAC form) | Rat, subcutaneous | Plasma presence beyond 72 h | Pharmacokinetic evaluation | Jetté and colleagues, 2005 |
| CJC-1295 (DAC form) | Rat plasma | Albumin-band species from 15 min to beyond 24 h | Western blot | Jetté and colleagues, 2005 |
| CJC-1295 (no-DAC, modified GRF 1-29) | Animal models | Minutes to tens of minutes (descriptive) | Not specified in the cited primary papers | Summarized in the research overview |
The absence of a primary half-life value for the no-DAC compound in the sources above should be stated openly in any methods section. Where a number is needed, a laboratory can measure it in its own system, as described below.
Pharmacodynamic persistence versus plasma persistence
A molecule’s presence in plasma and its biological effect are different quantities. In GHRH knockout mice exposed for five weeks, once-daily CJC-1295 gave normal body weight and length, while the same amount given every 48 or 72 hours gave less complete growth (Alba and colleagues, 2006). Plasma presence beyond 72 hours in rats would not alone predict that the longer intervals fall short, which indicates that effect depends on concentration over time and on receptor and somatotroph responses. The no-DAC analog adds a further point: with a pulsatile axis, a short exposure may be the intended design. Pulsatile infusion of a short GRF fragment promoted growth in rats where continuous infusion did not (Clark and Robinson, 1985).
Formulas a laboratory actually needs
Four relationships cover most pharmacokinetic reasoning on a bench.
| Quantity | Formula | Use |
|---|---|---|
| First-order decay | C(t) = C₀ · e−kt | Concentration remaining at time t |
| Half-life | t½ = ln 2 ÷ k ≈ 0.693 ÷ k | Convert a fitted rate constant to time |
| Fraction remaining after n half-lives | (½)n | Quick estimate: after 5 half-lives about 3% is left |
| Accumulation with repeated exposure at interval τ | R = 1 ÷ (1 − e−kτ) | Ratio of steady-state to single-exposure peak, for first-order decay |
| Area under the curve | AUC = ∫ C(t) dt (trapezoid rule on sampled points) | Overall exposure; used by Jetté and colleagues to compare GH output |
The accumulation formula shows why exposure interval relative to half-life matters in a design. With a half-life much shorter than the interval, R is close to 1 and each exposure is independent, which suits pulse designs. With a half-life longer than the interval, R grows and exposures overlap, which is the situation a long-acting conjugate creates. These are formulas, not recommendations for any schedule.
Measuring half-life in your own system
- Choose the matrix: buffer, serum-containing medium, plasma or animal tissue. Persistence depends on it, as the human-plasma data show.
- Incubate at 37 °C and remove samples at planned times; stop enzymatic activity at once (acidification or a protease inhibitor are common choices).
- Measure the intact peptide by a method that separates it from its fragments. HPLC does this; an immunoassay that cross-reacts with the cleavage product can overstate persistence (the 63-versus-17-minute contrast).
- Fit ln C against t. The slope is −k. Compute t½ = 0.693 ÷ k and report the matrix, temperature and method.
- Check for adsorptive loss with a no-enzyme control, because peptides stick to plastic and this mimics decay (Goebel-Stengel and colleagues, 2011).
The general analytical background is in understanding HPLC purity and HPLC versus mass spectrometry.
Practical points for working with the supplied peptide
The CJC-1295 (No DAC) page lists a lyophilized powder, 5 mg and 10 mg vials, ≥98% HPLC purity and storage at 2–8 °C, or −20 °C for long term, protected from heat, moisture and light. Because the molecule is a substrate for plasma peptidases, any experiment in serum-containing medium needs a time-matched control and should not be compared with one in buffer. Concentrations are mass divided by volume (the calculator does it), and the preparation method is in how to reconstitute a lyophilized peptide. Related analogs are compared in CJC-1295 versus sermorelin, and certificates, where published, sit in the COA library.
Frequently asked questions
What is the half-life of CJC-1295?
It depends on the form and the system. For the DAC form, a rat study reported plasma presence beyond 72 hours. For the no-DAC form, primary half-life data are limited and it is described as short-lived, minutes to tens of minutes in animal models.
Why is native GHRH so short-lived?
A plasma dipeptidyl peptidase removes the first two residues, producing a nearly inactive product. By HPLC the intact 44-mer had a half-life of 17 minutes in human plasma in vitro.
How does the DAC group extend persistence?
It contains a maleimide that bonds covalently to cysteine 34 of serum albumin, so the peptide circulates attached to a long-lived carrier.
Why do immunoassay and HPLC half-lives differ?
The immunoassay detects the inactive cleavage product as well as intact peptide, so it overstates persistence. HPLC resolves the two. In the native GHRH study the values were 63 and 17 minutes.
Does long plasma presence mean long biological effect?
Not necessarily. In knockout mice, exposure interval mattered even though the compound persisted for days in rats, because response depends on concentration over time and on cell responses.
What formula converts a rate constant to half-life?
t½ = ln 2 ÷ k, about 0.693 ÷ k.
How do I estimate remaining peptide after several half-lives?
Multiply by one half for each half-life: (½)^n. After five half-lives roughly 3% remains.
How can I measure the half-life of the no-DAC peptide?
Incubate it in the matrix of interest at a fixed temperature, sample over time, stop enzymes immediately, measure intact peptide by HPLC and fit ln C against time.
Can peptide loss to plastic look like degradation?
Yes. Adsorption lowers measured concentration without chemical change, so include a no-enzyme control in low-binding tubes.
Is this a guide to use outside the laboratory?
No. It summarizes published pharmacology and formulas. V8 supplies the peptide for laboratory research use only.
Related reading: CJC-1295 Purity: What an HPLC Percentage Cannot Show, How to Reconstitute CJC-1295 No DAC: Bench Workflow, CJC-1295 Research Reference Sheet: Terms and Numbers.
References
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the N terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
- Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9-24. doi:10.1016/S0167-0115(99)00089-0
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Clark RG, Robinson ICAF. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314(6008):281-283. doi:10.1038/314281a0
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
